2696 H1 2026 Results Presentation

Page 1

Page 2

© 2026 Henlius. Shanghai Henlius Biotech, Inc. (the “Company”, together with its subsidiaries, the “Group”) provides the following cautionary statement: This document contains certain forward-looking statements with respect to the operations, performance and financial condition of the Group, including, among other things, statements about expected or targeted revenues, margins, earnings per share or other financial or other measures, as well as the Group’s pipeline products and their expected development, regulatory approval and commercialisation timelines (including the Financial Ambition Statements (as defined below) described in this document). Although the Group believes its expectations and targets are based on reasonable assumptions and has used customary forecasting methodologies used in the biopharmaceutical industry and risk-adjusted projections for individual products (which take into account the probability of success of individual clinical trials, based on industry-wide data for relevant clinical trials at a similar stage of development), any forward-looking statements, by their very nature, involve risks and uncertainties and may be influenced by factors that could cause actual outcomes and results to be materially different from those predicted. The forward-looking statements reflect knowledge and information available at the date of preparation of this document and the Group undertakes no obligation to update these forward-looking statements. The Group identifies the forward- looking statements by using the words ‘anticipates’, ‘believes’, ‘expects’, ‘intends’ and similar expressions in such statements. Certain statements contained in this document that are not statements of historical fact constitute forward-looking statements, notwithstanding that such statements are not specifically identified. Important factors that could cause actual results to differ materially from those contained in forward-looking statements, certain of which are beyond the Group’s control, include, among other things: the risk of failure or delay in the development of pipeline candidates or launch of new products, considering that most of the Group’s drug candidates are still under development and are in the clinical development stages, and the course of clinical development involves a lengthy and expensive process with uncertainties in various aspects, as the Group can provide no assurance regarding development progress or clinical outcomes, and that if the clinical development and regulatory approval process of the drug candidates are delayed or terminated, the successful development and commercialisation of the Group’s drug candidates in a timely manner may be adversely affected; the risk of failure to meet regulatory or ethical requirements for medicine development or approval; the risk of failures or delays in the quality or execution of the Group’s commercial strategies; the risk of pricing, affordability, access and competitive pressures from pharmaceutical companies around the world in respect of various factors such as indication treatment, drug novelty, drug quality and reputation, breadth of drug portfolio, manufacturing and distribution capacity, drug price, breadth and depth of customer coverage, consumer behaviour and supply chain relationships; the risk of policies unfavourable to the Group, which may include the advancement and implementation of the relevant centralised procurement policies in the People’s Republic of China; the risk of failure to maintain supply of compliant, quality products; the risk of illegal trade in the Group’s products; the impact of reliance on third-party goods and services; the risk of failure in information technology or cybersecurity; the risk of failure of critical processes; the risk of failure to collect and manage data in line with legal and regulatory requirements and strategic objectives; the risk of failure to attract, develop, engage and retain a diverse, talented and capable workforce; the risk of failure to meet regulatory or ethical expectations on environmental impact, including climate change; the risk of the safety and efficacy of marketed products being questioned; the risk of adverse outcomes in litigation and/or governmental investigations; intellectual property-related risks to the Group’s products; the risk of failure to achieve strategic plans or meet targets or expectations; the risk of failure in financial control or the occurrence of fraud; the risk of unexpected deterioration in the Group’s financial position; the risk of any natural disasters or other unanticipated catastrophic events such as earthquakes, fires, terrorist attacks and wars; and the impact that global and/or geopolitical events may have, or continue to have, on these risks, on the Group’s ability to continue to mitigate these risks, and on the Group’s operations, financial results or financial condition. There can be no guarantees that the Company’s pipeline products will receive the necessary regulatory approvals, be successfully developed, manufactured, or commercialised. This presentation includes references to pipeline products that are being investigated in current or future clinical trials, and as such have not been approved by any regulatory agency. For the Group’s latest product portfolio and pipeline, see Henlius‘ official website: http://www.henlius.com. The basis of the Company’s ambitions, forecasts and targets in this document (the “Ambition Statements”) is derived from the Company’s most recent risk-adjusted mid- and long-term plans, adjusted for developments in the business since those plans were finalised. The Ambition Statements presented are based on management’s risk-adjusted projections for individual products and individual clinical trials. Estimates for these probabilities are based on industry-wide data for relevant clinical trials in the biopharmaceutical industry at a similar stage of development adjusted for management's view on the risk profile of the specific asset. Estimates are based on customary forecasting methodologies used in the biopharmaceutical industry. The development of biopharmaceutical products has inherent risks given scientific experimentation, and there is a range of possible outcomes in clinical results, safety, efficacy and product labelling. Clinical results may not support the desired product profile; the competitive environment, pricing, and reimbursement may have a material impact on commercial revenue forecasts. By their nature, forecasts are based on a multiplicity of assumptions and actual performance in future years may vary significantly and materially, from these assumptions. The Ambition Statements in this document are based on stated exchange rates. All subsequent written and oral forward-looking statements attributable to the Company or any person acting on its behalf are expressly qualified in their entirety by the cautionary statements referenced above. The Company undertakes no obligation to update those statements based on future currency movements. This document shall not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any offer, solicitation or sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of such jurisdiction. By attending the presentation relating to this document, or by reading this document, you agree to be bound by the above limitations. Shanghai Henlius Biotech, Inc. Forward-Looking Statements

Page 3

Page 4

© 2026 Henlius. ~4,000 50+ 50+ 8 5 84,000 L 4 4 Products Approved by the U.S. FDA Products Approved by the China NMPA Products Approved by the European Commission Ongoing Clinical Trials Early-stage Innovative Assets Global Employees Manufacturing Capacity Henlius (2696.HK): A Biopharma Company from China to the World benefiting ~ 1,100,000+ patients YoY growth: 27.3% 3.59B RMB 26H1 Revenue • 2026 H1 total revenue reached RMB 3.59B, up 27.3% YoY; global product revenue reached RMB 2.94B, up 14.9% YoY; ex-China product revenue reached RMB 0.11B, up 159.4% YoY. • 2026 H1 net profit reached RMB 0.43B, up 10.3% YoY; pre-R&D profit reached RMB 1.26B, up 28.8% YoY; Non-IFRS EBITDA reached RMB 0.9B, up 35.2% YoY; operating cash inflow reached RMB 0.56B. • In 2026 H1, 28 global BLA filings and 25 approvals across 15+ countries/regions demonstrate strong international regulatory capabilities. Highlights: - Serplulimab (brand name: HANSIZHUANG / Hetronifly®): Approved in China for Perioperative Gastric Cancer; 1L nsq-NSCLC, ESCC and sq-NSCLC approved in the EU; 1L ES-SCLC approved in Korea (July 1, 2026) and formally enters routine use in the NHS following NICE recommendation - Pertuzumab (brand name: HANBEIYOU / POHERDY®): Approved in China, the UK and the EU - Denosumab (brand name: BILDYOS® / TUZEMTY®): Approved in Canada YoY growth: 35.2% 904M RMB 26H1 EBITDA* © 2026 Henlius. * Non-IFRS EBITDA

Page 5

© 2026 Henlius. Total Revenue 3.59B +27.3% Global Product Revenue* 2.94B +14.9% Key Financial Indicators (in RMB) 2026 1H Key Metrics (in RMB 100 Million) R&D Expenditure 1.45B +45.7% 0.83B +41.1% Expensed R&D Expenditure 2026 1H Key Metrics (in RMB 100 Million) 5 * Includes overseas product supplyrevenue and royalty revenue. # Non-IFRS EBITDA 25H1 26H1 Significant YoY Growth in Pre-R&D Profit and Ex-China Product Revenue in 1H 2026 Pre-R&D Profit 1.26B +28.8% 0.90B +35.2% EBITDA # Ex-China Product Revenue* 0.11B +159.4% Net Profit 4.30B +10.3% 25H1 26H1 2.6 +159% 1.1 0.4 Ex-China Product Revenue +146% 6.5 2.6 BD & Other Income +15% 29.4 25.6 Global Product Revenue +27% 35.9 28.2 Total Revenue 10.0 +41% Expensed R&D Expenditure Pre-R&D Profit +46 % +29% 14.5 8.3 +10% Profit 4.3 3.9 12.6 6.6 EBITDA +35% 9.0 5.9 9.8 R&D Expenditure

Page 6

© 2026 Henlius. In Next Few Years, More Then 10+ Products Are Expected To Be Launched Globally Serplulimab(5) mCRC(JP) Serplulimab(5) LS-SCLC(CN,US,EU) mCRC(CN) ES-SCLC(JP) PD-L1 ADC(16) LC(CN,US,EU) TC(JP) HER2(17) GC Lasofoxifene(21) SERM BC Serplulimab(5) GC(JP) FUTUONING(8) (fovinaciclib, CDK4/6) In-Licensed Assets PD-L1 ADC(16) TC EGFR(20) CSCC PD-L1 ADC(16) LC(CN,US,EU,JP) HANNAIJIA(6) (neratinib) Serplulimab(5) ES-SCLC (PD-1) 3rd EGFR-TKI(24) NSCLC HER2 ADC(15) BC Nivolumab(12) Solid Tumor H+P HAase(14) BC Bevacizumab(4) BILPREVDA® (7) (denosumab) Serplulimab(5) ESCC, LC(EU) Neo/adj. GC (CN) Serplulimab(5) ES-SCLC (US) Neo/adj. GC (EU) Cetuximab(13) mCRC Pembrolizumab(11) Solid Tumor Evolocumab(22) Hypercholesterolemia PD-L1 ADC(16) LC (JP) HANDAYUAN(3) (adalimumab) HERCESSI (2) (trastuzumab) BILDYOS® (7) (denosumab) Pertuzumab(9) BC (EU, CN) VEGF(10) wAMD Nivolumab(12) Solid Tumor Daratumumab(19) MM Daratumumab (19) MM EGFR(20) LC, mCRC HANLIKANG(1) (rituximab) HANQUYOU(2) Zercepac® (trastuzumab) HANBEITAI(4) (bevacizumab) HANSIZHUANG(5) (PD-1) Rituximab(1) POHERDY® (9) (pertuzumab) Bevacizumab(4) (US) Denosumab(7) Osteoporosis & Oncology, etc. Pembrolizumab(11) Solid Tumor Ipilimumab(18) Solid Tumor Ipilimumab(18) Solid Tumor Dupilumab(23) Atopic dermatitis, asthma (1) HLX01, approved in China and multiple Latin American countries. The first biosimilar approved in China. Business partners: Fosun Pharma/ Eurofarma/ Abbott/ Boston Oncology. (2) HLX02, approved in 50+ countries, including China, U.S., the UK, Germany, France and Australia, trade name in U.S.: HERCESSI . Trade name in Europe: Zercepac®. Business partners: Accord/ Elea/ Eurofarma/ Abbott/ KGbio/ Getz Pharma. (3) HLX03, approved in China, business partners: Fosun Wanbang/ Getz Pharma. (4) HLX04, approved in China and multiple Latin American countries. Business partners: Eurofarma. (5) HLX10, approved in 50 countries and regions, including China, the UK, Germany, India, Singapore, trade name: Hetronifly® in Europe. Business partners: KGbio/ Fosun Pharma/ Intas/ Lotus/ Abbott/ Eisai. (6) HLX901, commercialization in China. (7) HLX14, approved in North America and Europe, Business partner: Organon. Trade name: BILDYOS® (60mg/mL), BILPREVDA® (120mg/1.7mL) in the U.S. and Europe. Marketing applications are under review in China (60mg/mL). (8) HLX902, commercialization in China. (9) HLX11, approved in the U.S, Europe and China. Trade name: POHERDY® in the U.S. and Europe. Marketing applications are under review Canada. Business partner: Organon. (10) HLX04-O, NDA under review in China. Business partner: Essex. (11) HLX17. (12) HLX18. (13) HLX05-N. (14) HLX319. (15) HLX87, the development and exclusive commercialization rights obtained in China and select ex-China markets. . (16) HLX43, IND approvals obtained in China/the U.S./Japan/Australia / Europe. (17) HLX22 (dulpatatug), IND approvals obtained in China/the U.S./Japan/the EU, Generic name under pINN status. (18) HLX13, business partner: Sandoz, etc. (19) HLX15, business partner: Dr. Reddy‘s, etc. (20) HLX07, received IND approvals in China and the US. (21) HLX78, exclusive license obtained in China. Phase 3 MRCT enrolling globally. IND approval obtained in China. (22) HLX16. (23) HLX1102. (24) HLX903, exclusive commercialisation rights and development rights in Chinese Mainland and Macau The biosimilar pipeline fuels innovation with robust cash flow Entered Globalization 2.0, more products will be launched globally* Launched globally Biosimilar Innovative Drugs Launched in China 2026 2027 2028 20292025 2030 2031+2024202220212019 2020 Entering the Globalization 2.0 *The Company's internal planning time is subject to the actual situation, and shareholders and potential investors of the Company are advised to exercise caution when trading the Company's shares. 6

Page 7

© 2026 Henlius. Asset Code Target/MOA Indication Stage HLX37 PDL1xVEGF BsAb CC, HCC, NSCLC, solid tumor Phase I HLX316 B7-H3 sialidase fusion protein NSCLC, OC, PC Phase I HLX97 KAT6A/B inhibitor BC Phase I HLX3901 DLL3xDLL3xCD3xCD28 TCE SCLC Phase I HLX48 c-METxEGFR ADC CRC, LC Phase I HLX3902 STEAP1xCD3xCD28 TCE prostate cancer Phase I HLX49 Her2xHer2 ADC BC, GC Pre-IND HLX105 PD1xIL2v BsAb solid tumor Pre-IND HLX403 CDH17 ADC GI cancer Pre-IND HLX402 ADAM9 ADC solid tumor Pre-IND HLX85 ALPP/ALPPL2 ADC solid tumor (OV, PAAD, STAD, TGCT, MESO, UCEC, CESC) Pre-IND HLX41 LIV1 ADC BC Pre-IND HLX86 Her2 dual-payload ADC BC Pre-IND Asset Code Target/MOA Indication Stage HLX109 IL-1R3 mAb atopic dermatitis, psoriasis, etc. Pre-IND HLX68 TL1AxIL23(p19) BsAb IBD (UC, CD) Pre-IND HLX67 FcRnxHSA BsAb IgG-mediated diseases Pre-IND HLX320 TSHRxIGF1R BsAb Thyroid eye disease Pre-IND HLX702 IL-23R oral cyclic peptide PsO, PsA, IBD Pre-IND 7 Asset Code Target/MOA Indication Stage HLX203 ActRIIA/B Ab Lean Mass Management Pre-IND HLX204 GPCR Agonist Lean Mass Management Pre-IND HLX69 FXI/FXIa mAb TKA, stroke prevention in AF, cancer-associated VTE, etc. Pre-IND Neurology & Metabolism I&IOncology Global Innovation Center pipelines

Page 8

© 2026 Henlius. Europe Broad cooperation across key countries • MD Anderson Cancer Center • Memorial Sloan Kettering Cancer Center • National Cancer Center Hospital (NCCH); • National Cancer Center Hospital East (NCCHE); • Kindai University Hospital (Faculty of Medicine, Kindai University); • Cancer Institute Hospital of the Japanese Foundation for Cancer Research (JFCR) Collaboration with Leading Institutions 20+ 10,000+ Countries Patients (1,700+ from ex-China) Sites 1,000+ CRO-free for key regions(CN, US, JP, AU), with an in-house clinical team of ~750 professionals, 54 staff from the USA, and 48 staff from other overseas regions Japan Strategic partnership with top hospitals USA Extensive network of leading clinical sites China Strong in-house presence and site network Australia Collaborating with leading institutions 8 Leveraging our global in-house clinical capabilities, Henlius is committed to delivering high-quality, efficient, and patient-centric clinical trials worldwide. Global In-House Clinical Team Covering Key Regions

Page 9

© 2026 Henlius. The strategic, operational, and innovation core center, driving global alignment and resource optimization across all markets. Strategic Command: Orchestrating global initiatives and capital allocation. Core Competency Hub: Steering alliances, portfolio strategy, and pricing. Decision Authority: Final governance for major investments and entry strategies. Local operational anchors that translate global strategy into actionable, culturally resonant execution for regional markets. Insight & Execution: Adapting products and campaigns to local consumer needs. Stakeholder Engagement: Nurturing key relationships with governments and other relevant organizations. P&L Ownership: Driving regional profitability and budget accountability. International Market (IM) Core Team Commercial Alliance Manage strategic alliances with partners to drive growth and expand market share. Foster innovation and unlock new global market opportunities. Affiliate Commercial Build an in-house commercial team. Enhance commercial capabilities and accelerate market penetration in key territories. Market Access & Pricing Develop data-driven global pricing & market access strategies. Ensure patient affordability while maximizing product competitiveness. Commercial Strategy & Operations Build commercial strategy, ensuring alignment with global business goals and driving efficiency across markets. Medical Affairs Build strategic medical leadership to guide US product launch and lifecycle strategy, and build execution excellence in patient- centric medical activities. Strategic Global Presence Anchor for Becoming a C-MNC With In-house Commercialization Capabilities 9 Global Headquarters (China) Regional Hubs

Page 10

© 2026 Henlius. Asia-PacificEurope With 6 Global Partners Covering 50+ Markets 3 Differentiated Indications Targeting a RMB 10B+ Global Peak Sales • U.S.: Bridging study enrollment for all 200 patients completed; Data readout in 2026; BLA submission expected in 2026 • Canada: Build in-house commercial capabilities to maximize commercial value • EU: 4 indications approved, incl. SCLC, sq/nsq-NSCLC and ESCC, commercially launched in 17 European countries and included in national reimbursement lists in 12 countries, including the UK, Germany, Italy and Sweden • UK: Formally enters routine use in the NHS following NICE recommendation, becoming the 1st PD-1 inhibitor for ES- SCLC in England and Wales • China: Perioperative gastric cancer indication approved in China, with global development advancing in parallel; 1L mCRC Ph 3 Study enrollment completed in China, Japan and SEA; MRCT data readout expected in 2027 • Japan: Partnering with Eisai to embark on a new journey in Japan; BLA for ES-SCLC expected in 2027 H1; 1L mCRC,Ph 3 study patient enrollment completed; Adj/neo-adj GC bridging study in preparation • Global approvals are steadily advancing across South Korea, Latin America, Southeast Asia and other regions Lung Cancer Gastric Cancer Colorectal Cancer North America 10 Serplulimab: Next China-developed Innovative Drug to Achieve RMB 10B+ Global Sales

Page 11

© 2026 Henlius. Patients Enrolled (Solid Tumors) *Incident cases: new cases per year estimated from GLOBOCAN 2022 data in US+EU5+CN+JP US patients *Data cutoff: Aug 2026 HLX43 (PD-L1 ADC) 1,500+ >50% Patients with NSCLC 100+ Mechanism of Action • Receptor-mediated internalization • Bystander effect via payload release in TME, mediated by metalloproteinases and cysteine proteases • Immuno-Oncology effects Pan-Tumor Efficacy • Broad antitumor activity across multiple tumor types • Activity independent of PD-L1 expression status Safety Profile • Manageable hematologic toxicities with low incidence of thrombocytopenia • MRCT led by top global KOLs • Primary endpoint: ORR (IRRC) • Countries and regions involved: CN, US, EU, AUS, and JP • Key milestone:As of Aug 19, 2026, a total of 236 patients had been enrolled globally, with 147 patients ex-China (96 from US, 18 from AUS, 13 from JP, and 20 from EU). 11 HLX43-NSCLC201: PD-L1 ADC Phase 2 Trial in Later-Line NSCLC Pyrimidine Coupling Tripeptide Linker Camptothecin Payload Anti-PD-L1 hIgG1 DAR=8 Seeking Accelerated Approval (AA) in CN and the US Incident Cases (k) LoT Regimen Clinical Stage Released Data 1,411 nsqNSCLC ≥2L HLX43 Mono Pivotal Planned cORR 36.8%, PFS 6.67m Non-AGA 1L HLX43±HLX10 Ph2 - sqNSCLC 2L HLX43±HLX07 Ph2/3 sqNSCLC ≥2L HLX43 Mono Ph2 cORR 46.7%, PFS 6.90m 250 1L ≥2L HLX43±HLX10 HLX43 Mono Ph2 - 6 ≥2L HLX43 Mono Ph2 1,081 2L HLX43+HLX04±Chemo HLX43+HLX07 HLX43+HLX10 Ph2 - 559 ≥2L HLX43 Mono Ph2 - 239 ≥2L HLX43 Mono Ph2 ORR: 61.5%, DCR 100% 710 ≥2L HLX43 Mono Ph2 - 140 1L CPS<10: HLX43 Mono CPS≥10: HLX43+HLX10 Ph2 - 2L HLX43 Mono Ph2 - 225 1L HLX43+HLX10±HLX07 Ph2 - 56 ≥3L HLX43 Mono Ph2 ORR: 70%, DCR 80% 191 ≥2L HLX43 Mono Ph2 ORR: 70%, DCR 100% 122 Platinum- resistant HLX43 Mono Ph2 NSCLC SCLC mCRC GC ESCC HR+BC HNSCC NPC CC TNBC OC TSCC HLX43 (PD-L1 ADC): High Efficacy, Low Toxicity, and IO Functionality

Page 12

© 2026 Henlius. HLX43 (PD-L1 ADC): NSCLC Study Results at Potential RP2/3D BICR-assessed efficacy & Baseline characteristics 2.0 mg/kg Sq-NSCLC (n = 33) 2.5 mg/kg Nsq-NSCLC EGFR wild-type (n = 19) 2.5 mg/kg Nsq-NSCLC EGFR mutant (n = 16) Confirmed ORR % (95% CI) 33.3 (18.0, 51.8) 36.8 (16.3, 61.6) 37.5 (15.2, 64.6) Docetaxel failed (≥ 3L) (n = 15) 46.7 (21.3, 73.4) Confirmed DCR % (95% CI) 81.8 (64.5, 93.0) 94.7 (74.0, 99.9) 87.5 (61.7, 98.4) Docetaxel failed (≥ 3L) (n = 15) 80.0 (51.9, 95.7) Median PFS (95% CI), months 6.34 (4.07, 7.13) 6.67 (4.14, 8.25) 5.55 (4.04, NE) Docetaxel failed (≥ 3L) (n = 15) 6.90 (1.35, 8.28) PD-L1 expression by TPS#, n (%) TPS < 1% 16 (48.5) 7 (36.8) 12 (75.0) 1% ≤ TPS < 50% 11 (33.3) 9 (47.4) 1 (6.3) TPS ≥ 50% 5 (15.2) 0 3 (18.8) Not available 1 (3.0) 3 (15.8) 0 Prior lines of therapy Median (range) 2.0 (1–7) 2.0 (1–6) 2.0 (1–9) Prior platinum-based chemo, n (%) 33 (100.0) 19 (100.0) 16 (100.0) Prior immunotherapy, n (%) 33 (100.0) 19 (100.0) 6 (37.5) Prior targeted therapy, n (%) 11 (33.3) 7 (36.8) 16 (100.0) Prior docetaxel, n (%) 15 (45.5) 3 (15.8) 2 (12.5) # Detected with SP263. chemo, chemotherapy; ECOG PS, Eastern Cooperative Oncology Group performance status; EGFR, epidermal growth factor receptor; NSCLC, non-small cell lung cancer; Nsq, nonsquamous; PD-L1, programmed death-ligand 1; RP3D: recommended Phase 3 dose; sq, squamous; TPS, tumor proportion score. BICR, Blinded Independent Central Review; CI, confidence interval; DCR, disease control rate; EGFR, epidermal growth factor receptor; L, line; NE, not estimable; NSCLC, non-small cell lung cancer; ORR, objective response rate; PFS, progression-free survival; PD-L1, programmed death-ligand 1; TPS, tumor proportion score. TRAEs, n (%) 2.0 mg/kg Sq-NSCLC (n = 33) 2.5 mg/kg Nsq-NSCLC (n = 35) Any TRAE 31 (93.9) 35 (100.0) Grade ≥3 14 (42.4) 20 (57.1) Most Common Grade ≥3 (≥ 10%) Lymphocyte count decreased 7 (21.2) 13 (37.1) WBC count decreased 1 (3.0) 9 (25.7) Neutrophil count decreased 1 (3.0) 8 (22.9) Anemia 3 (9.1) 6 (17.1) Pneumonia 1 (3.0) 4 (11.4) TRAEs leading to Tx interruption 9 (27.3) 16 (45.7) TRAEs leading to Tx discontinuation 2 (6.1) 4 (11.4) TRAEs leading to Tx reduction 0 (0.0) 10 (28.6) TRAEs leading to death 0 (0.0) 0 (0.0) 12

Page 13

© 2026 Henlius. HER2 Trastuzumab (HLX02) HLX22 domain IV Indication Gastric Cancer Breast Cancer • Dual-epitope HER2 therapy • Boosts HER2 internalization by 40–80% • Potential to break 1L treatment barriers in HER2+ GC Dulpatatug (HLX22, novel epitope HER2) • Ph2 1L HER2+ GC: sustained PFS/OS benefit • Ph3 1L HER2+ GC MRCT: head-to-head comparison vs 1L SOC (trastuzumab + chemotherapy ± pembrolizumab) GC BC HLX22 significantly prolonged PFS and had a manageable safety profile (median follow-up period of 28.5 months). HLX22+ Tras + XELOX (n=31) Zanidatamab + CAPOX/FP (n=304, 300 patients treated) TEAEs Leading to death 0 (0.0%) 25 (8.2%) TRAEs, Any-Grade 30 (96.8%) 296 (97.0%) TRAEs, Grade≥3 9 (29.0%) 180 (59.0%) Discontinued due to TRAE 2 (6.5%) 105 (34.4%) Treatment-Related Diarrhea, Any Grade <15% 233 (76.4%) Treatment-related Diarrhea, Grade≥3 0 (0.0%) 61 (20.0%) HLX22-GC301 PHAROS001 MRCT led by top global clinical researchers Dr. Shen Lin Beijing Cancer Hospital CSCO GC Chair Dr. Jaffer A. Ajani MD Anderson NCCN GC Chair Dr. Ken Kato NCCH JCOG ESCC Convocator Dr. Kohei Shitara National Cancer Center Hospital East (NCCHE) ESMO Upper GI Chair Dr. Yelena Janjigian Memorial Sloan Kettering Cancer Center ESMO Chair R 1:1 Primary Endpoints: PFS, OS • FPI: November 22, 2024 • As of Aug 18, 2026, the global cumulative enrollment reached 428 patients, with 58.4% from CN, 4.7% from the US, 11.9% from EU, 12.1% from JP, and 12.9% from other regions (including SK, AUS, and LATAM) • Key data readout is expected in H2 2027. 8% 4% 60% 20% 8% 13 Dulpatatug* (HLX22, novel epitope HER2 mAb): Ongoing PHAROS001 Phase 3 MRCT in GC and Phase 2 Exploration in BC PHAROS001 Key Milestone • Ph2 2L HER2-low BC trial ongoing(HLX22+T-Dxd) • Ph2 ≥2L HER2+ BC previously treated with Trastuzumab Deruxtecan trial SSU (HLX22+ Trastuzumab) • Ph2&3 1L HER2+ BC trial SSU (HLX22 + HLX87 HER2 ADC) 1. J Clin Oncol. 2025 43(suppl 4):abstr 440; 2. Lancet. 2023. 402(10418):2197; 3. J Clin Oncol 44, 2026 (suppl 2; abstr LBA285); 4. Yelena Y J.2024 ESMO. HLX22 + SOC ±placebo(Keytruda), Q3W Placebo (HLX22) + SOC ±Keytruda, Q3W R 1:1 PHAROS001 Planned Enrollment Percentage *The generic name is in the pINN status.

Page 14

Page 15

© 2026 Henlius. Expansion New Abbott Expansion ORGANON Henlius leverages its strengths of R&D and manufacturing in China while partnering with global pharmaceutical companies to expand commercialization around the world. Partnered Product: HLX13 (ipilimumab) Regions covered: the U.S., 42 European countries and regions, Japan, Canada and Australia Partnered Product: HLX05-N (cetuximab), HLX16 (evolocumab), belimumab, etc. up to 10 biosimilar products Regions covered: ex-China Partnered Product: Serplulimab (Hetronifly® in Europe) Regions covered: Europe, India Partnered Product: HLX15 (daratumumab) Regions covered: the U.S. and 43 countries and regions in Europe Partnered Product: Serplulimab (Hetronifly® in Europe) Regions covered: Indonesia Partnered Product: HLX02 (trastuzumab, HERCESSI in the U.S., Zercepac® in Europe) Regions covered: 7 countries in Southeast Asia Partnered Product: HLX01 (rituximab), HLX03 (adalimumab) Regions covered: China Partnered Product: Serplulimab (Hetronifly® in Europe) Regions covered: the U.S. Partnered Product: HLX03 (adalimumab), HLX02 (trastuzumab, HERCESSI in the U.S., Zercepac® in Europe) Regions covered: South Asia, Central Asia, Southeast Asia, and African countries. Partnered Product: Serplulimab (Hetronifly® in Europe) Regions covered: South Korea Partnered Product: Serplulimab (Hetronifly® in Europe) Regions covered: Japan Partnered Product: HLX01 (rituximab), HLX02 (trastuzumab, HERCESSI in the U.S., Zercepac® in Europe), Serplulimab (Hetronifly® in Europe), 4 biosimilars products Regions covered: Brazil; 71 emerging markets in Asia, LAC, North Africa, etc. Partnered Product: HLX11 (pertuzumab), HLX14 (denosumab, BILDYOS® & BILPREVDA® in the U.S. and the EU) Regions covered: Global (excluding China, Hong Kong, Macau, Taiwan) Partnered Product: HLX02 (trastuzumab, HERCESSI in the U.S., Zercepac® in Europe) Regions covered: Over 70 countries and regions (including the U.S., Canada, and Europe) Partnered Product: HLX01 (rituximab) Regions covered: Arab countries, North Africa, and 16 other markets Partnered Product: HLX02 (trastuzumab, HERCESSI in the U.S., Zercepac® in Europe) Regions covered: Argentina, Uruguay, Paraguay Partnered Product: HLX01 (rituximab), HLX02 (trastuzumab, HERCESSI in the U.S., Zercepac® in Europe), HLX04 (bevacizumab) Regions covered: 16 Latin American countries Partnered Product: HLX04-O (bevacizumab) Regions covered: Global 15 © 2026 Henlius. Growing Global Commercialization: Partner of Choice!

Page 16

© 2026 Henlius.16 EISAI CO., LTD. LA signed: 2026.02.05 HLX10 (Serplulimab) Exclusive rights in Japan Upfront: $75M Total Size2: $388.34M Abbott Products Operations AG LA signed: 2026.02.24 HLX10 (Serplulimab) Emerging market expansion SEA, MENA RA Milestones: $46M Total Size: $126M Jiangsu Chuangte & CTFH LA signed: 2026.05.18 FHND9041 (3rd Gen EGFRi) EGFRmut NSCLC NDA Submitted Exclusive Rights in Mainland China & MC Backbone for EGFRmut Lung Cancer In-LicensingOut-Licensing1 Sandoz Group AG LA signed: 2026.08.16 Up to 10 Biosimilar Products First collaboration includes: HLX05-N (cetuximab), HLX16 (evolocumab), belimumab, HLXTE-HAase1001 (option) Ex-China3 First Collaboration Upfront: $77M Non-refundable Option Payment For Hyaluronidase: $8M 2026 Expected Invoiced Amount to be Achieved : $100.5M 40% of the net sales or net profits 2026 H1 BD Deal Highlights 1. Payments pursuant to the terms of the agreement. 2. The total size comprises upfront, development, regulatory, and sales milestone payments, with actual receipts contingent upon the achievement of mutually agreed milestones and conditions. 3. In respect of HLX05-N, the exclusive territories to register and commercialize shall cover the United States, Canada, the countries of the European Economic Area, Switzerland, the United Kingdom, Japan, Australia, and New Zealand; and the semi- exclusive territories to register and commercialize shall cover agreed certain countries/regions in Asia as well as other regions. In respect of HLX16 and Belimumab biosimilar, the exclusive territories to register and commercialize shall cover worldwide excluding Chinese Mainland and Hong Kong, Macau and Taiwan regions of China.

Page 17

© 2026 Henlius. HLX17- Pembrolizumab PD-1 317.2 HLX18- Nivolumab PD-1 119.1 HLX12- Ramucirumab VEGFR-2 11.1 HLX16- Evolocumab PCSK9 30.7 HLX1102- Dupilumab IL-4Rα 170.0 HLX1105- Romosozumab ESOST 26.6 HLX319- pertuzumab+ trastuzumab HER2 27.7 HLX03- Adalimumab TNF-α 60.3 Partners in ASEAN, North Africa, and other regions HLX15- Daratumumab CD38 143.5 European, U.S., and other regional partners Partners in the EU, U.S., Canada, ASEAN, and North Africa HLX02- Trastuzumab HER2 66.0 Abbott HLX04- Bevacizumab VEGF 28.1 Partners in Latin America and other regions HLX01- Rituximab CD20 32.3 Partners in North Africa, Latin America, and other regions Abbott 17 Biosimilars to be out-licensed US/EU Market Market Size of Originators and Marketed Biosimilars Global sales in 2025 (100M USD) Out-licensing Focus: Henlius’ International Quality Biosimilars Provide Stable Cash Flow and Support Innovative Pipelines Biosimilars with existing out-licensing partners Global sales in 2025 (100M USD) Data Source: Global dataPotentially first biosimilar in EU and the U.S. Global potentially first biosimilar Organon HLX14- Denosumab RANKL 72.9 Ex-China Partners Sandoz HLX13- Ipilimumab CTLA-4 29.0 European, U.S., and other regional partners HLX11- Pertuzumab HER2 33.7 Ex-China Partners Organon HLX05- Cetuximab EGFR 20.0 Belimumab BAFF 27.3 Ex-China Partners Sandoz

Page 18

© 2026 Henlius. In-Licensing: Late-Stage Focused on Breast and Lung Cancer to Maximize Commercial Synergies; Early-Stage Focused on Oncology and Immunology 2024 2025 2026 2027 2028 2029 2030 Neratinib Neratinib Fovinaciclib Neratinib Fovinaciclib Neratinib Fovinaciclib HLX903 (EGFR TKI) Neratinib Fovinaciclib HLX903 (EGFR TKI) HLX87 (HER2 ADC) Neratinib Fovinaciclib HLX903 (EGFR TKI) HLX87 (HER2 ADC) HLX78 (Lasofoxifene) Neratinib Fovinaciclib HLX903 (EGFR TKI) HLX87 (HER2 ADC) HLX78 (Lasofoxifene) HLX701 (SIRPα-Fc) RMB 45M RMB 303M HLX78 (Lasofoxifene) A next-generation oral selective estrogen receptor modulator (SERM) for HR+/HER2− breast cancer 2024, Exclusive Asian Rights Revenue Contribution Trend of BD In-Licensed Products Strong Growth Expected in Revenue from In-Licensed Products HLX87 (GQ1005) Late-stage HER2-ADC asset that complements the HER2-positive breast cancer portfolio 2025.12, Exclusive Rights in China (and designated regions in emerging markets) HLX901 (Neratinib) In-licensed HER2-targeted TKI asset, creating strong commercial synergies with HANQUYOU 2024.08, Exclusive Rights in China Mainland (and conditional right in designated ex-China regions) HLX902 (Fovinaciclib) In-licensed CDK4/6 inhibitor for the treatment of HR+ breast cancer 2025.12, Exclusive Rights in China Mainland Lung Cancer HLX903 (FHND9041) Late-stage third-generation EGFR-TKI asset that strengthens the lung cancer commercial portfolio. Demonstrated best-in-class efficacy potential in patients with EGFR exon 19 deletion mutations, with median PFS exceeding 26 months. China NDA currently under review. 2026.05, Exclusive Rights in China Mainland & Macau HLX701 (HCB101) SIRPα-Fc fusion protein and next-generation immuno-oncology therapy. Being explored for colorectal cancer (CRC) treatment with encouraging early efficacy signals. Phase II clinical development is ongoing. 2025.06, Exclusive Rights in China Mainland, HK, MC, designated countries in Southeast Asia and MENA Overview of BD In-Licensed Assets Solid Tumor Breast Cancer 18

Page 19

Page 20

© 2026 Henlius. Next Generation IO Hanjugator ADC Platform Immune Cell Engager HAI Club platform • PD-(L)1–based next-generation ICIs • Addressing Immune Checkpoint Inhibitor Resistance • Improving Clinical Response to ICIs • Larger therapeutic window • Overcome potential drug resistance • Combination of toxins with multiple MOAs • Sustained, antigen-specific T-cell activation • Enhanced efficacy in the tumor microenvironment (TME) • Reduced risk of CRS • De novo generation powered by Generative AI and LLMs • Multi-parametric toxicity prediction for efficient screening • Leveraging proprietary intelligence for druggability modeling Comprehensive World-class Technology Platforms as an Innovation Powerhouse >7 assets >12 assets >5 assets © 2026 Henlius.20

Page 21

© 2026 Henlius. 21 • Broader Therapeutic Window: Reduced IL2 receptor binding capacity to improve peripheral safety profile, achieving a higher HNSTD compared to the reference drug, 12 mpk vs 3mpk • Superior In Vivo Efficacy: Outperforms the reference drug at comparable HNSTD-adjusted dose levels • Better In Vitro Activity: Enhanced PD-1 blockade and IL2 signaling activation on target cells • Favorable CMC Profile: Demonstrates excellent manufacturability with high production and purification yields Anti-PD1 Anti-PD1 IL2m (alpha-bias) • IL-2 Variant Bias Profile: similar to the reference drug • Reduced IL2 receptor binding capacity • Bi-valent PD1 Fab to enhance anchoring • IND filing expected in 2026 H2 59.2% 50.6% 97.8% 62.7% 90.7% TGI% (day 28) 0 7 14 21 28 35 0 1000 2000 3000 4000 Efficacy in CT26 CRC CDX in BALB/c-hPD1 KI mice Days after treatment (d) Tumor Volume (mm3) Vehicle HLX10(Henlius,Anti-PD1), 3.33 mpk HLX105, 0.4 mpk (3.3% HNSTD) HLX105, 1.22 mpk (10% HNSTD) TAK-928/IBI363, 0.29 mpk (10% HNSTD) TAK-928/IBI363, 0.86 mpk (28.6% HNSTD) Vehicle HLX10, 3.33 mpk 0.4 mpk 1.22 mpk 0.29 mpk 0.86 mpk 0 20 40 60 80 100 CR rate in hPD1-CT26 model on day28 CR rate (%) HLX105 TAK-928/IBI363 20% 57% 33.3% 0% 0% • At 10% of the HNSTD, HLX105 achieved almost total tumor inhibition. • HLX105 showed deeper tumor suppression and a higher complete response rate compared to the reference drug. • The HNSTDs of HLX105 and the reference drug are 12 mg/kg and 3 mg/kg, respectively. HLX105 demonstrated better efficacy than the reference drug at a lower fraction of the HNSTD in a CRC model HLX105 (PD-1 x IL2v) Highlights HLX105 (PD1xIL2v): A next-generation safer immunotherapy for pan-solid tumors Reference Drug Reference Drug Reference Drug

Page 22

© 2026 Henlius. 22 HLX49 (HER2 x HER2 ADC) • With low payload potency and low DAR design (pilot tox HNSTD: 120 mg/kg), the clinical dose is expected to reach above 10 mg/kg to maximize the function of antibodies. • Presenting the antibody function and payload cytotoxicity • Indications include the HER2-positive, HER2-low BC and GC, etc. • IND filing expected in 2026 H2 Hydrophilic Unit A29GGFG Proprietary Linker Payload HLX02 anti-HER2 HLX22 anti-HER2 ( special epitope ) LP (DAR4) Low potency and low DAR TGI, day 28 42.8% 73.9% 109.6% 54.8% At a lower percentage of its HNSTD, HLX49 achieved better efficacy than the reference drug in BC and GC PDX models. Highlights HR+ HER2 IHC 1+ BC PDX CDK4/6i treated clinically HER2 IHC 3+ GC PDX Herceptin and chemo-treated clinically HR+HER2 IHC 1+ BC PDX AI+CDK4/6i, DS-8201 sequential treated clinically HLX49: Developing a Novel HER2 x HER2 Bi-paratopicADC for BC and GC 733±298 (no PR) 142±32 (1 PR) TV mm3 (day 38) 0 10 20 30 0 250 500 750 1000 1250 days post treatment TV (mm3) Vehicle (PBS) DS-8201, 6 mg/kg (20% HNSTD) HLX49, 6 mg/kg (5%HNSTD) HLX49, 9 mg/kg (7.5%HNSTD) HLX49, 12 mg/kg (10% HNSTD) GC PDX, Balb/c nude, HER2 single dose, i.v., n=7/group p<0.05 0 7 14 21 28 35 42 0 500 1000 1500 2000 2500 3000 3500 4000 Days post administration Tumor volume (mm3) BC PDX, HR+HER2 IHC 1+ single dose, n=4/group DS-8201, 3 mpk （10% HNSTD） HLX49, 3 mpk (2.5% HNSTD) HLX49, 6 mpk (5% HNSTD) Vehicle DS-8201, 1.5 mpk （5% HNSTD） HLX49, 1.5 mpk (1.25% HNSTD) * 0 10 20 30 40 0 1000 2000 HR+ HER2 IHC 1+ BC PDX, CDK4/6i treated clinically; single dose, n=7/group, NPG mice days post treatment Tumor Volume (mm3) Vehicle (5% Glucose) DS-8201, 6 mpk (20% HNSTD) HLX49, 6 mpk （5% HNSTD) HLX49, 9 mpk (7.5% HNSTD) Reference Drug Reference Drug Reference Drug Reference Drug

Page 23

© 2026 Henlius. Expected IND Approval FPI to be achieved HLX3902 (STEAP1xCD3xCD28) May 2026 (AUS) June 2026 (CN) July 2026 (CN) HLX105 (PD-1xIL2) Expected Oct. 2026 (AUS) Expected Nov. 2026 (CN) Expected Oct. 2026 (AUS) HLX109 (IL-1R3mAb) Expected Oct. 2026 (AUS) Expected Nov. 2026 (CN) Expected Oct. 2026 (AUS) HLX49 (HER2xHER2 ADC) Expected Nov. 2026 (AUS) Expected Dec. 2026 (CN) Expected Nov. 2026 (AUS) HLX403 (CDH17 ADC) Expected Dec. 2026 (AUS) Expected Jan. 2027 (CN) Expected Dec. 2026 (AUS) 23 2025 H2-2026 H1 Ongoing Clinical Trials 5 Expected to enter clinical development in 2H26 5 Innovative Drug IND Plan in 2025–2026 IND Approval FPI Achieved HLX37 (PD-L1xVEGF) November 2025 December 2025 HLX3901 (DLL3xDLL3xCD3xCD28) March 2026 April 2026 HLX97 (KAT6A/B Inhibitor) March 2026 May 2026 HLX316 (B7-H3 Sialidase Fusion Protein) March 2026 May 2026 HLX48 (cMETxEGFRADC) May 2026 (AUS) May 2026 (CN) June 2026 (CN)

Page 24

Page 25

© 2026 Henlius. Global MRCT Approved in Global marketsBridging study in U.S. Innovative ADCInnovative mAb Innovative fusion protein small molecule Innovative multi-specific antibody BLA under FDA review Biosimilar mAb HLX15 (2) (daratumumab) CD38 Multiple myeloma HLX13 (3) (ipilimumab) CTLA-4 Melanoma, HCC, etc. HLX05-N (3) (cetuximab) EGFR mCRC, HNSCC (1) Exclusive rights in China (excl. Taiwan), several countries in Southeast Asia, and other selected countries and regions; Phase 1b/2a conducting in countries such as China and the U.S. (2) IND approvals obtained in China/the U.S. Business partner: Dr. Reddy‘s, etc. (3) Business partner: Sandoz, etc. (4) IND approvals obtained in China/the U.S. (5) Approved in 50 countries and regions, including China, the UK, Germany, India, Singapore, trade name: Hetronifly® in Europe. Business partners: KGbio/ Fosun Pharma/ Intas/ Lotus/ Abbott/ Eisai. (6) IND approvals obtained in China/the U.S./Japan/the EU, , Generic name under pINN status. (7) IND approvals obtained in China/the U.S./Japan/Australia / Europe. (8) The development and exclusive commercialization rights obtained in China and select ex-China markets. (9) Exclusive license obtained in China. (10) Approved in China and multiple Latin American countries. The first biosimilar approved in China. Business partners: Fosun Pharma/ Eurofarma/ Abbott/ Boston Oncology. (11) NDA under review in China. Business partner: Essex. (12) Exclusive license obtained in China. Phase 3 MRCT enrolling globally. IND approval obtained in China. (13) Approved in North America and Europe, Business partner: Organon. Trade name: BILDYOS® (60mg/mL), BILPREVDA® (120mg/1.7mL) in the U.S. and Europe. Marketing applications are under review in China (60mg/mL). (14) Approved in China and multiple Latin American countries. Business partners: Eurofarma. (15) Exclusive commercialisation rights and development rights in Chinese Mainland and Macau. (16) The first rituximab approved for the indication in China. (17) Approved in 50+ countries, including China, U.S., the UK, Germany, France and Australia, trade name in U.S.: HERCESSI . Trade name in Europe: Zercepac®. Business partners: Accord/ Elea/ Eurofarma/ Abbott/ KGbio/ Getz Pharma. (18) Business partners: Fosun Wanbang/ Getz Pharma. (19) Approved in the U.S, Europe and China. Trade name: POHERDY® in the U.S. and Europe. Marketing applications are under review Canada. Business partner: Organon. (20) Commercialization in China. Serplulimab (5) PD-1 sqNSCLC, ES-SCLC, ESCC, nsqNSCLC, GC HLX01 (rituximab) (10) CD20 NHL, CLL, RA (16) HLX02 (trastuzumab) (17) HER2 BC, mGC HLX03 (adalimumab) (18) TNF-α RA, AS, Ps, UV, pJIA, pediatric Ps, CD, pediatric CD HLX04 (bevacizumab) (14) VEGF mCRC, NSCLC, GBM, HCC, EOC, FTC or PPC, CC Serplulimab (5) + HLX07 (4) (pimurutamab) PD-1+EGFR Solid tumors (sqNSCLC, etc.) HLX07 (4) (pimurutamab) EGFR Solid tumors (cSCC , etc.) HLX43 (7) PD-L1 ADC Solid tumors (NSCLC, etc.) Serplulimab (5) + Chemo + Radio PD-1 LS-SCLC 1L HLX04-O (11) VEGF Wet AMD Serplulimab (5) + Chemo PD-1 ES-SCLC 1L Serplulimab (5) + bevacizumab + Chemo PD-1+VEGF mCRC 1L HLX22 (dulpatatug) (6) + trastuzumab + Chemo HER2+HER2 GC HLX78 (lasofoxifene) (12) SERM BC HLX17 (pembrolizumab) PD-1 Solid tumors (NSCLC, TNBC, etc.) HLX37 PD-L1 x VEGF BsAb Solid tumors HLX316 B7H3 x Sialidase Solid tumors HLX3902 Steap1 x CD3 x CD28 TsAb PCa HLX105 PD1 x IL2v Solid tumors HLX41 LIV-1 ADC BC HLX48 cMET x EGFR BsADC NSCLC, CRC HLX97 KAT6A/B ERα+ Breast Cancer HLX6018 GARP/TGF-β1 IPF HLX43 (7) + Serplulimab (5) PD-L1 ADC + PD-1 Solid tumors HLX14 (denosumab) (13) RANKL Osteoporosis, Cancer-related bone disease, etc. HLX22 (dulpatatug) (6) + T-DXd HER2 HER2-low/HR+ BC HLX79 (9) + HLX01 (rituximab) (10) Sialidase Fc Fusion Protein + CD20 Active Glomerular Diseases HLX18 4) (nivolumab） PD-1 Solid tumors (NSCLC, MEL, etc.) HLX701 (1) CD47-SIRPα Blockade Solid tumors HLX04-O (11) VEGF Wet AMD HLX901 (neratinib) (20) HER1/HER2/HER4 BC BILDYOS®(denosumab) (13) RANKL Osteoporosis, etc. BILPREVDA® (denosumab) (13) RANKL Cancer-related bone disease, etc. Fovinaciclib (20) CDK4/6 BC POHERDY® (pertuzumab) (19) HER2 BC HLX04 (bevacizumab) (14) VEGF mCRC, NSCLC, GBM, HCC, CC, EOC, etc. HLX87 (8) + HLX22 (dulpatatug) (6) HER2 ADC + HER2 BC 1L HLX319 (Pertuzumab + Trastuzumab, SC) HER2+HER2 BC HLX109 IL-1R3 Autoimmune diseases (AD, Psoriasis, etc.) HLX49 HER2 x HER2 ADC Solid tumors (HER2+ BC/GC, etc.) HLX403 CDH17 ADC Gastrointestinal cancers HLX87 (8) HER2 ADC BC HLX3901 DLL3 x DLL3 x CD3 x CD28 TetraAb SCLC HLX903 (15) EGFR-TKI NSCLC 1L HLX208 (9) BRAF V600E Solid tumors HLX203 ActRIIA/B lean mass management HLX68 TL1A x IL23(p19) BsAb IBD (UC、CD, etc.) HLX320 TSHR x IGF1R BsAb TED Phase 2 Phase 3Pre-IND/IND Phase 1 Marketing Applications Approved Product portfolio and pipeline 25

Page 26

© 2026 Henlius. H1 H2* 26 EU: nsqNSCLC, sqNSCLC, ESCC China: GCneo (Priority Review & Breakthrough Therapy Designation) Korea: ES-SCLC Serplulimab 5 Indications Approved SCLC JP bridging study enrollment completed Serplulimab Clinical Progress First patient dosed in 5 Ph2 POC trials: In combination with Serplulimab for NSCLC; in combination with Serplulimab/HLX07 for CRC and NSCLCneo; and 2 BC trials. First patient dosed in 1 Ph2/3 trial: MRCT Ph2/3 for sqNSCLC HLX43 Clinical Progress Dulpatatug# (HLX22) Clinical trials advancing, overseas accelerated Pimurutamab (HLX07) First-patient-dosed in Ph2 of sqNSCLC MRCT Ph2/3; CSCC Ph2 is ongoing HLX22 & HLX07 Clinical Progress SCLC approval expected in multiple emerging markets nsqNSCLC, sqNSCLC & ESCC to be filed in Switzerland, LATAM & ASEAN Serplulimab BLA Approval & Submission SCLC JP bridging study expected to reach primary endpoint Serplulimab Clinical Progress Multiple PoC data readouts: In combination with Serplulimab/HLX07 First patient dosed in 2 trials: SCLC; in combination with Bevacizumab for CRC Initiate 1 pivotal study: 2L nsqNSCLC HLX43 Clinical Progress Dulpatatug# (HLX22) Enrollment to be completed for 2 trials: MRCT for GC Ph3, and CN Ph2 in combination with HLX87 for BC. First-patient-dosed in 2 trials: CRC Ph2, Ph2 for Trastuzumab Deruxtecan-pretreated BC Data readout for 1 trial: BC Pimurutamab (HLX07) Enrollment to be completed for 2 trials: Ph2 of sqNSCLC MRCT Ph2/3, first stage of CSCC Ph2 HLX22 & HLX07 Clinical Progress 2026 Expected Clinical Milestones: Progress in Late-stage Innovative Drug Pipeline *2H 2026 information is based on the Company's internal plans and forecasts and has not yet been realized. Actual results are subject to regulatory approvals.# The generic name is in the pINN status.

Page 27

© 2026 Henlius. 27 6 trials First-patient-in 2 trials Continuous Enrollment 1 trial Dose escalation completed 5 trials Continuous enrollment 4 trials Enrollment completion 1 trial Stage completion H1 H2* Milestone in 2026: Progress in Early Innovative Drug Pipeline HLX701 (SIRPα-IgG Fc fusion protein) January CN IND Approval HLX316 (B7H3 Sialidase Fusion Protein) HLX37 (PD-L1 x VEGF bispecific Antibody) HLX48 HLX3901 HLX3902 HLX97 HLX78 HLX87 HLX79 March FPI achieved Q4 Target to complete dose escalation and safety evaluation March CN IND Approval May FPI achieved Continuous enrollment Continuous enrollment July Mono-therapy dose escalation and safety evaluation completed Q3 FPI for combo-therapy dose escalation and mono-therapy expansion Q4 Ph2/3 FPI Continuous enrollment Continuous enrollment Continuous enrollment Continuous enrollment March AU CTN Approval May CN IND Approval June FPI achieved April FPI Achieved May AU CTN Approval June CN IND Approval July FPI Achieved March CN IND Approval May FPI Achieved Continuous enrollment Q4 Expect to complete MRCT enrollment in ER+/HER2- BC February HLX87 + HLX22 (Dulpatatug#) achieved FPI of CN Ph2 study for 1L HER2+ BC July Achieved LPI of CN Ph2 study for 1L HER2+ BC Q3 Expect to achieve LPI of CN Ph3 study for 2L HER2+ BC March Dose escalation and safety evaluation completed Q3 Expect data readout for MN indication *2H 2026 information is based on the Company's internal plans and forecasts and has not yet been realized. Actual results are subject to regulatory approvals.# The generic name is in the pINN status. (cMET x EGFR ADC) (DLL3 x DLL3 x CD3 x CD28 TCE) (STEAP1 x CD3 x CD28 TCE) (KAT6A/B) (Lasofoxifene) (HER2 ADC) (Sialidase Fc Fusion Protein)

Page 28

© 2026 Henlius. 28 BLA Approval ｜ 2 Products HLX01 Rituximab sNDA for the new indication of the innovator drug in China was approved on April 7, 2026 HLX11 Pertuzumab EU marketing authorisation granted on April 23, 2026;CN NDA approval on May 27 and UK MAA approval on May 29 BLA Submission/Review ｜ 6 Products HLX01 Rituximab MAA under review in Brazil, approval estimated in 2026-2027 HLX02 Trastuzumab MAA under review in Chile, approval estimated in 2026-2027 HLX03 Adalimumab MAA under review in Philippines, Kazakhstan, and Kenya, approval estimated in 2026-2027. HLX04 Bevacizumab US BLA under review, approval estimated in Nov. 2026 HLX11 Pertuzumab BRA NDA submitted on March 27, 2026, approval estimated in Mar. 2027- Sep. 2027, CAN NDS under review, approval estimated in Dec 2027 HLX14 Denosumab NMPA BLA submission for indications (GCTB, etc.) is expected in Q3 2026 Pivotal PK Study Initiation/Enrollment｜ 5 Products HLX05-N Cetuximab CN IND approved on April 13, 2026; US IND approved on May 8, 2026. Pivotal Ph1 PK study initiated, FPI achieved on July 8, 2026 HLX15 Daratumumab Pivotal Ph1 PK study of SC formulation initiated, FPI achieved in May 2026 HLX17 Pembrolizumab Pivotal Ph1 PK study initiated, LPI estimated in Aug. 2026 HLX18 Nivolumab Pivotal Ph1 PK study initiated, FPI achieved on July 16, 2026. HLX319 Pertuzumab and Trastuzumab SC CN IND approved on March 31, 2026, FPI achieved on April 9, 2026, Pilot PK study is ongoing USA *HLX04 Bevacizumab BLA under review Brazil * HLX01 Rituximab MAA under review * HLX11 Pertuzumab NDA Submitted Canada * HLX11 Pertuzumab NDS under review Chile * HLX02 Trastuzumab MAA under review EU/UK * HLX11 Pertuzumab Approved Philippines, Kazakhstan, Kenya * HLX03 Adalimumab MAA under review 2026 Approvals and NDA Submissions 2026 Clinical Milestones: Rapid Advancement of Global Biosimilar Development *2H 2026 information is based on the Company's internal plans and forecasts and has not yet been realized. Actual results are subject to regulatory approvals. China * HLX01 Rituximab Approved * HLX11 Pertuzumab Approved * HLX14 Denosumab Target to complete NMPA BLA submission of 120mg in Q3 2026

Page 29

© 2026 Henlius. Modified Humanized Monoclonal Antibody Targeting EGFR Indication First-line treatment of sqNSCLC with high EGFR expression (H-score ≥ 150) *Approximately 89% of patients with sqNSCLC have high expression Pimurutamab (HLX07, EGFR) Compared with cetuximab • Lower immunogenicity • Higher target affinity • Extended half-life • Longer administration interval • Well-suited for combination with IO therapies • Synergistic effects when combined with PD-1 inhibitors 29 HLX10HLX07-sqNSCLC-201: a randomized, multicenter Ph2 dose-finding trial Positive Efficacy Signals (Median Follow-Up: 18.6 Months) mPFS 17.4 months DCR 100% ORR 71.4% mOS Not Reached Significant Mechanistic Advantages of HLX07 Pimurutamab(HLX07, EGFR mAb): Enables Dual-target Synergy, Pioneering a New Path for 1L-treatment of EGFR-high-Expression sqNSCLC * Information is based on the Company's internal plans and forecasts and has not yet been realized. Actual results are subject to regulatory approvals. • Ph 2/3 IND/CTN approval: AUS CTN approved in January 2026, CN IND approved in March, GEO CTA approved in April • FPI: May 2026 • Progress: Ph2 is ongoing, mPFS data readout is expected in Aug. 2027* • Next stage: Ph3 expected to begin in Q4 2027* • Potential indications: sqNSCLC and CSCC R 1:1 Group A: HLX07 1,000 mg + Serplulimab + Chemo, Q3W X 4 Cycles (N=50) Group C: Placebo + Serplulimab + Chemo, Q3W X 4 Cycles (N=50) R 1:1:1 Group B: HLX07 600 mg + Serplulimab + Chemo, Q3W X 4 Cycles (N=50) HLX07 1,000 mg + Serplulimab, Q3W HLX07 600 mg + Serplulimab, Q3W Placebo + Serplulimab, Q3W Maintenance Primary endpoints: PFS, ORR HLX07-sqNSCLC-301: a randomized, double-blind, multicenter Phase 2/3 clinical evaluates HLX07+serplulimab +chemotherapy as a 1L treatment for advanced sqNSCLC Group A (n=13) Group B (n=14) ORR, % (95% CI) 69.2 (38.6-90.9) 71.4 (41.9-91.6) DCR, % (95% CI) 92.3 (64.0-99.8) 100.0 (76.8-100.0) Complete response, n (%) 0 (0.0) 0 (0.0) Partial response, n (%) 9 (69.2) 10 (71.4) Stable disease, n (%) 3 (23.1) 4 (28.6) Progressive disease, n (%) 1 (7.7) 0 (0.0) Not evaluable, n (%) 0 (0.0) 0 (0.0) Tumor Response Status

Page 30

© 2026 Henlius. HLX701 (SIRPα–Fc fusion protein) is a fusion protein with a differentiated design, fused with engineered SIRPα and IgG4 Fc • High binding affinity to CD47 on tumor cells, and low binding affinity to CD47 on erythrocytes; • Effectively activates macrophage-mediated phagocytosis of tumor cells via the IgG4 Fc; • Specifically binds to CD47 on tumor cells compared to first-generation anti-CD47 antibodies; • Significantly enhances the affinity to CD47 compared to second-generation wild-type SIRPα fusion proteins1. Preliminary clinical data displayed good safety profiles and positive efficacy signal • To date, 10 dose levels have been evaluated, and the safety data have been reviewed by the Safety Review Committee (SRC). • Monotherapy has shown tumor responses in patients with solid tumors, and the preliminary efficacy of combo therapy is significant; PR has been observed in solid tumors such as HNSCC and TNBC. • With dual mechanisms of activating both innate immunity (macrophages) and adaptive immunity (T cells), there’re broad opportunities in combination therapies with various therapeutic medicines (e.g. PD-1/L1 mAb, chemotherapy, ADCs, etc. ). The cornerstone of next-generation IO therapy • IND:CN IND approved in January 2026 • FPI:March 2026 • Progress: Entered into FIH study mono dose escalation stage • Next stage: Expected to start the dose expansion exploration in 2026 H2* • Potential indications: RAS/BRAF wild-type CRC HLX701: Next-Generation CD47 IO Therapy, SIRPα-Fc fusion protein 30 Project Progress 1. The affinity of HCB101 to CD47 is 100-fold higher than that of wild-type SIRPα under specific animal models. 2. It’s observed that HCB101 could activate both innate immunity (macrophages) and adaptive immunity (T cells) under specific animal models. * Information is based on the Company's internal plans and forecasts and has not yet been realized. Actual results are subject to regulatory approvals.

Page 31

© 2026 Henlius. HLX3901(DLL3xDLL3xCD3xCD28 2025 IND 31 • HLX3901 is a novel tetraspecific antibody targeting DLL3, DLL3, CD3, and CD28. By employing an anti-DLL3 Fab fragment and an anti-DLL3 VHH nanobody that recognize different epitopes, this construct achieves superior target specificity. Furthermore, the integration of CD28-mediated costimulation substantially augments antitumor efficacy and attenuates T-cell exhaustion. Key Strengths: • Longer persistence of activated T cells with secondary T cell signaling • Greater efficacy in solid tumor treatment • Improve the therapeutic window of T cell engagers in solid tumors. αCD3e αCD28 αDLL3 (VHH) αDLL3 (Fab) Fc • IND:CN IND approved in March 2026 • FPI:April 2026 • Progress: Entered into FIH study mono dose escalation stage • Next Stage: Expect to start the mono dose expansion and combo therapy studies in Q2 2027* • Potential Indications: 1L ES-SCLC, LS-SCLC without progression after concurrent chemoradiotherapy 2026 IND • IND: AUS CTN approved in May 2026; CN IND approved in June 2026. • FPI:July 2026 • Progress: Entered into FIH study mono dose escalation stage • Next stage: Expect to start the mono therapy expansion and combo therapy studies in Q2 2027* • Potential indications: mCRPC, mHSPC HLX3902(STEAP1xCD3xCD28) • HLX3902 is an anti-STEAP1 × CD3 × CD28 trispecific antibody, which significantly reduces T-cell exhaustion and enhances therapeutic efficacy, thereby widening the therapeutic window. • Superior antitumor activity was associated with increased T-cell infiltration, proliferation, and persistence in the tumor microenvironment. Well-tolerated in cynomolgus monkeys. Potential best-in- class molecule Key Strengths: • Longer persistence of activated T cells with secondary T cell signaling • Greater efficacy in solid tumor treatment • Improve the therapeutic window of T cell engagers in solid tumors. 31 Project Progress Project Progress HLX3901 & HLX3902: Next-generation TCE platform incorporating CD28 as a co- stimulatory signal * Information is based on the Company's internal plans and forecasts and has not yet been realized. Actual results are subject to regulatory approvals.

Page 32

© 2026 Henlius. HLX97 KAT6A/B inhibitor 32 • IND: CN IND approved on March 4, 2026 • FPI: May 13, 2026 • Progress: Entered into FIH study mono dose escalation • Next stage: Expected to start the combo therapy studies in Q1, 2027* • Potential indication: HR+BC HLX48 (cMETxEGFR ADC) Molecule: EGFRxcMET Anti-cMET Anti-EGFR Hydrophilic Unit Linker Topoi 2026 IND 2025 IND • IND:AUS CTN approved on March 26, 2026; CN IND approved on May 20, 2026. • FPI:June 30, 2026 • Progress: Entered into FIH study mono dose escalation • Next stage :Expected to start the mono therapy expansion and combo therapy studies in 2027 H2* • Potential indications: NSCLC, CRC, HNSCC HLX97: A Potential Best-In- Class KAT6A/B Inhibitor Core Advantages: • Broad oncology applications including BC, CRPC, and NSCLC • Superior in vitro and in vivo efficacy compared to competitors • Unique PK profile mitigates accumulation and on- mechanism hematologic toxicity • Favorable ADMET* profile Project Progress Project Progress Core Advantages: • Widen the therapeutic window to maximize antibody function, enhance the bystander effect, and address tumor heterogeneity. • The HNSTD of HLX48 is 60 mg/kg, and HLX48 achieves better efficacy at a lower percentage of the HNSTD dose. The affinity for c-Met is higher than that for EGFR, reducing on-target toxicity in normal tissues. The affinity for c-Met is 12 times higher than that of the EGFR arm. • HLX48 features a low-potency payload, low DAR, and a strong bystander effect; its clinical dose is expected to reach 8 mg/kg or higher, maximizing antibody function while retaining payload-mediated cytotoxicity. HLX48: A Safer, More Efficacious cMET x EGFR ADC for LC and CRC * Information is based on the Company's internal plans and forecasts and has not yet been realized. Actual results are subject to regulatory approvals.

Page 33

Page 34

© 2026 Henlius. ～1.70 billion RMB +10.4% RRevenue in 1H2026 34 Breast Cancer Sales Revenue 4 Breast Cancer Products Launched Industry-leading Breast Cancer Commercial Team ～670-person Dedicated sales team Top-tier scale in the industry Highly specialized academic promotion team > 500K RMB per month (Sales per capita in 1H2026) Industry-leading commercialization efficiency Comprehensive Coverage 320+ cities 4,800+ hospitals 26,000+ customers Approved in May 2026 Breast Cancer:Industry-leading Commercialization Capabilities

Page 35

© 2026 Henlius. 深耕乳腺癌领域,全面覆盖乳腺癌不同亚型 , HR+/HER2-乳腺癌 Advanced Breast Cancer Early Breast Cancer HER2+乳腺癌疾病类型 Launched To be launched Trastuzumab + pertuzumab SC (HLX319) To be launched Lasofoxifene (HLX78) KAT6A/B (HLX97) Dulpatatug* (HLX22) Launched Launched TNBC To be launched HR+/HER2-BCHER2+BC Deep Expertise in Breast Cancer, Covering All Key Subtypes PD-L1 ADC (HLX43) 35 To be launched HER2 ADC (HLX87) HER2 BsAb ADC (HLX49) *The generic name is in the pINN status Breast Cancer: Commercialization Success Fuels a Robust Pipeline

Page 36

© 2026 Henlius. Pipeline Products to Be Launched • PD-L1 ADC (HLX43) • cMet x EGFR BsAb ADC (HLX48) • EGFR TKI (HLX903) 36 Comprehensive Coverage of Lung Cancer Treatment • nsqNSCLC Industry-leading Lung Cancer Commercial Team ～500-person Dedicated sales force • Strong professional communication & proven oncology promotion experience • Highly specialized academic promotion team Comprehensive Coverage • 300+ cities • 3,400+ hospitals • 22,000+ customers Precise Targeting • Strengthen the first-line preferred option status in SCLC and consolidate market share • Adopted a differentiated strategy to precisely target the brain metastases population and rapidly develop the NSCLC market Lung Cancer: Strong Commercialization Capabilities Support a Comprehensive Portfolio • ES-SCLC • sqNSCLC • nsqNSCLC

Page 37

© 2026 Henlius. • ESCC • GC: Perioperative GC indication approved in June • CRC: First IO approval expected in 1L non-MSI-H mCRC Upcoming pipeline launches • PD-L1 ADC (HLX43) • Dulpatatug* (HLX22) • PD-L1 x VEGF BsAb (HLX37) 37 GI Cancer • mCRC Tailor differentiated strategies to the specific characteristics of each tumor type Deliver precision treatment concept and increase market share in EC market • Leverage the significant efficacy in the PD- L1 CPS≥10 population to promote precision medicine to maximize patient benefit, establish a preferred first-line position, and expand market share in the esophageal squamous cell carcinoma market. Ushering in A new era of chemo-free immunotherapy for GC • As of the date of this material, the world’s first and only anti-PD-1 monoclonal antibody approved for a perioperative gastric cancer indication, filling a major clinical treatment gap • The world’s first postoperative “chemo-sparring” perioperative regimen for gastric cancer, replacing adjuvant chemotherapy with immunotherapy monotherapy, significantly reducing the risk of recurrence and bringing curative treatment within reach • Establish a dedicated GC team to develop targeted market strategies in advance, capture the perioperative gastric cancer “blue ocean” market, benefit more patients • The international multicenter Phase 3 clinical study of Serplulimabas a first-line treatment for non-MSI- H mCRC (ASTRUM-015) has completed patient enrollment. • It is expected to become the world’s first anti–PD-1 monoclonal antibody for first-line treatment of non-MSI-H mCRC, addressing a significant unmet need in first-line immunotherapy. Anticipate data readout from the global multicenter Phase 3 mCRC study GI Cancers: The Only Anti-PD-1 Monoclonal Antibody Approved For Perioperative GC, Building A Core Strategic Pillar For The Future *The generic name is in the pINN status

Page 38

Page 39

© 2026 Henlius. NMPA & Shanghai MPA FDA & EMA PIC/S Members and EU QP Audit Henlius achieved a 100% pass rate in on-site inspections across all countries. 40+ 7 10+ 20+ 100% Xuhui Site 24,000 L GMP-certified by China, the EU, and PIC/S members (Brazil, Indonesia, etc.) Songjiang Site I 24,000 L GMP-certified by China, the EU, and the U.S. Songjiang Site II 36,000 L GMP-certified by the EU, and the U.S. Commercial production of over 1,400 GMP batches, success rate > 98% Global Partner Audit Regulatory Approval Success Rate 39 World-class Biopharmaceutical Platform

Page 40

© 2026 Henlius. 40 Tapping Internal Potential Lean Operations Digitalization empowers production scheduling and enhances human efficiency. Under the premise of zero capital expenditure (CAPEX), it is expected to increase the capacity of existing commercial production lines by over 10%. Continuous Capacity Expansion Plan to establish a new scale-out production line at Songjiang Site II, enabling flexible commercial manufacturing at scales ranging from 2,000 L to 6,000 L. External Expansion Capacity Co-construction Plan to co-established a scale production line with partners. Optimize cash flow investment while reducing costs through large-scale production. Oversea CMO Source overseas CMOs that meet the highest standards of EU and US cGMP. Enhance supply chain responsiveness and delivery timeliness to support Henlius product expansion in overseas markets. Capacity Expansion Strategy

Page 41

© 2026 Henlius. H1 Business Progress & Deliveries HLX10 • 4 new countries/SKUs • No delayed delivery HLX14 • 2 new countries/4 SKUs • 6+ countries/12 SKUs from approval New RegionsHLX02+BWFI HLX11 • Henlius’ marketed biosimilar • 7 days from approval to package New Products • First co-package products • First cross-site products Manufacturing, Supply, CMC, Global Submission and Post-marketing Management • 1,400+ commercial DS batches; 98.6% success rate • 15 clinical-supply batches, 100% success rate [1400+ Batches DS] 01 Supply Assurance • HLX04-O｜Inspection response completed • HLX11｜5.29 CN/4.29 EU approved;Brazil under review • HLX14｜3.24 Canada approved;China audit completed • HLX10｜Apr. Turkey audit completed;Jul. Korea GMP approved; FDA BLA ready; • HLX04｜May FDA on-site audit [5 Projects] [7 Countries] 03 Global Submission & Audit • 5 ADCs: HLX48/HLX49/HLX402/HLX403/HLX43; 2 late- stage programs: HLX18/HLX07 • AT3002/HLX13/HLX17/HLX05/HLX22, 20PPQ • HLX04-O, HLX10 G2 NDA submission ready [5+2 IND] [6 Technical Transfer] [2 NDA] 02 CMC pipeline • HHLX14LX02 + BWFI Co-pack FDA approved,BWI Canada approved • DP4 EMA approved (2026.02.10) • HLX02 G2.1 EMA approved (2026.04.10) • HLX02 420mg • HLX01 NMPA BLA submitted(2026.02) [Cover FDA / EMA / NMPA][4 Approvals] [1 Submission] 04 Post-marketing Management H1 Global Launch partners 3 Products 4 Countries 7 First Launches 9 Oversea Deliveries 18 Delayed Delivery 0 41 China USA EU Turkey Canada Brazil Korea HLX10 2026.01.16 Peru HLX14 2026.03.31 HLX14 2026.04.23 HLX10 2026.05.15 Brazil HLX10 2026.06.05 HLX02 2026.06.05 2026.06.05 HLX11 2026.06.16 Italy Canada HLX10 2026.04.22 Mexico Paraguay Brazil China HLX02+BWFI Canada

Page 42

© 2026 Henlius. End-to-end Cost Reduction and Efficiency 42 • Replacement with high-expression cell lines which significantly increases single-batch output • Optimizing chromatography and purification processes improves overall product yield Process Upgrade Process Upgrade Large-scale Manufacture Supply Chain Reshaping • Plan to build a new scale production line and a flexible scale-out production line to reduce product costs • Co-construction mode significantly dilutes fixed cost amortization (such as plant and equipment) and labor costs Large-scale Manufacture • Promote the local replacement of core high-value consumables such as culture media, filters, resin, and disposable reaction bags • Potentiate supply chain resilience, shorten procurement lead time, and reduce logistics and inventory turnover costs Supply Chain Reshaping

Page 43

Page 44

Page 45

© 2026 Henlius. Global Product Sales • Global product sales, including overseas product supply revenue and royalty revenue, amounted to RMB 2.94B in 2026 1H, 15.1% YoY growth • Sales of HANQUYOU and HANLIKANG increased steadily, while sales of HANBEITAI and HANNAIJIA grew rapidly Revenue Growth • Revenue of RMB 3.59B in 2026 1H, a 27.3% YoY growth • Revenue growth mainly driven by sales ramp-up of core products in China and ex-China, andBD income • Gross profit of RMB 2.77B in 2026 1H, a 25.9% YoY growth • HANQUYOU: RMB 1.47B China sales in 2026 1H, 4.7% YoY growth • HANSIZHUANG: RMB 573M China sales in 2026 1H, -3.4% YoY growth • HANLIKANG: RMB 325M China sales in 2026 1H, 18.3% YoY growth • HANDAYUAN: RMB 30M China sales in 2026 1H, 8.6% YoY growth • HANBEITAI: RMB 218M China sales in 2026 1H ,87.6% YoY growth • HANNAIJIA: RMB 195M China sales in 2026 1H, 102.0% YoY growth • BD, ex-China product sales and other income: RMB 755M in 2026 1H, 148.9% YoY growth 2026 1H Revenue Breakdown (in RMB 100 Million) Global Product Sales (in RMB 100 Million) Revenue (in RMB 100 Million) 45 24H1 25H1 26H1 24H1 25H1 26H1 26H1 25H1 Revenue Breakdown HANLIKANG (rituximab, CD20) HANQUYOU (trastuzumab, HER2) HANSIZHUANG (serplulimab, PD-1) HANBEITAI (bevacizumab, VEGF) HANNAIJIA (Neratinib) BD, product sales in overseas & other income Other Products 2026 1H Revenue of RMB 3.59 Billion, Global Product Revenue of RMB 2.94 Billion % of 26H1 Total Revenue 2.7% 27.5 28.2 35.9 27.3% 3.1% 24.8 25.6 29.4 14.9% 41.1% 9.0% 1.3% 16.0% 6.1% 5.4% 21.0% 3.2 2.7 14.7 14.1 5.7 5.9 2.2 1.2 2.0 1.0 0.5 0.3 7.5 3.0

Page 46

© 2026 Henlius. Positive OCF (in RMB 100 Million) Net profit: Sustained profitability (in RMB 100 Million) Net Profit Before Expensed R&D* (in RMB 100 Million) R&D related investment (in RMB 100 Million) Expense to revenue ratios 46 5.46 8.21 24H1 25H1 26H1 3.9 3.9 4.3 5.46 8.21 24H1 25H1 26H1 8.7 9.8 12.6 +13% +29% 24H1 25H1 26H1 4.8 5.9 8.33.4 3.0 4.1 1.3 6.2 1.7 11.3 11.2 16.2 24H1 25H1 26H1 0.9 2.5 7.7 3.5 5.6 24H1 25H1 26H1 24H1 25H1 26H1 24H1 25H1 26H1 24H1 25H1 26H1 33% 33% 35% 6% 7% 7% 18% 21% 23% 2% 2% 1% Net profit Cost of Services Provided* Capitalized Expensed * R&D spending related to out-licensing products is accounted for in the cost of services provided according to accounting practices * Expensed R&D costs are added back to net profit Net cash flows (used in) investing activities Net cash flows from (used in) operating activities Net cash flows from financing activities Net change in cash and cash equivalents Selling and distribution expenses R&D expensesAdministrative expenses Finance costs Achieved Profitability in 2026 1H with RMB ~559M Operating CF (5.6) (1.4) (6.6) (1.5) (6.2) (0.6) (10.5)

Page 47

© 2026 Henlius. Financial Data (selected) 26H1 25H1 YoY Growth Revenue 3,588.2 100.0% 2,819.5 100.0% 27.3% Product sales* 2,885.8 80.4% 2,556.8 90.7% 12.9% BD and other revenue 702.4 19.6% 262.8 9.3% 167.3% Cost of sales (820.0) (22.9%) (620.4) (22.0%) 32.2% Selling and distribution expenses (1,190.4) (33.2%) (987.8) (35.0%) 20.5% Administrative expenses (247.8) (6.9%) (185.4) (6.6%) 33.6% R&D expenses (826.0) (23.0%) (585.5) (20.8%) 41.1% Finance costs (51.8) (1.4%) (54.3) (1.9%) (4.6%) Net profit 430.4 12.0% 390.1 13.8% 10.3% Cash and bank balances 818.4 22.8% 853.5 30.3% (4.1%) Net cash flows from operating activities 559.4 15.6% 770.9 27.3% (27.4%) 47 Unit In Million RMB % of revenue In Million RMB % of revenue % *Excludeoverseas product royalty revenue. Financial Highlights

Page 48

© 2026 Henlius. • Henlius, the representor or the provider does not make express or implied warranties, statements or representations on the content of this document (the content of this document may also include forward-looking statements), including but not limited to the statements about the timeliness, universality and accuracy of the content for any specific purpose or with regard to the correctness of the information obtained by using the content of this document. If any conduct or consequence is caused due to any mistake, omission or incorrectness of relevant content, Henlius, the representor or the provider shall not be liable. • All rights, including copyrights, in this document and the content contained herein are exclusively owned by Henlius. The names “Henlius” and “复宏汉霖”, related designs, and logos are legally owned by Henlius. No third party may use them by any means including reproduction without written consent from Henlius. • The content of this document does not include and shall not be construed as any advice (including but not limited to medical advice and investment advice). You shall be liable for any decision made by yourself based on the content of this document. • This document contains forward-looking statements, offer declarations, and related risk warnings; please refer to the statement set forth on page 2 of this document. Disclaimer 48

Slides